INSMED Inc

INSMED Inc is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for serious respiratory and other high-unmet-need diseases. Its current business centers on marketed products ARIKAYCE and BRINSUPRI, while it also advances clinical and pre-clinical programs in respiratory, inflammation & immunology, and neuro/rare disease areas.

−203,9 %

79,7 %

−210,5 %

+66,7 %

3.83

3.54

— INSMED Inc
%
Commercial respiratory products100% Approved products sold today, led by ARIKAYCE and BRINSUPRI.
Respiratory clinical-stage programs0% Programs such as TPIP and INS1148 aimed at pulmonary and inflammatory airway diseases.
Inflammation & immunology pipeline0% Brensocatib development work targeting hidradenitis suppurativa and related inflammatory disease.
Neuro & rare disease gene therapy0% INS1201 and INS1202 programs for DMD and ALS, respectively.

INSMED sells primarily to healthcare providers and the specialty pharmacy / distributor channels that support...

  • Specialty respiratory prescribersprimary

    Pulmonologists and related specialists prescribe ARIKAYCE for refractory MAC lung disease and will be key for future respiratory launches.

  • Specialty pharmacy and distributor networkprimary

    Channel partners purchase, stock, and dispense product, making them central to revenue realization and patient access.

  • Payers and government reimbursement programsprimary

    Commercial insurers and public programs affect formulary access, rebates, and patient affordability for ARIKAYCE and BRINSUPRI.

  • Clinical investigators and trial centerssecondary

    Sites enrolling patients in TPIP, INS1148, INS1201, and INS1202 studies support pipeline advancement.

INSMED commercializes ARIKAYCE in the U.S., Europe, and Japan, and BRINSUPRI in the U.S...

  • •U.S. is the core market for BRINSUPRI and a major ARIKAYCE market
  • •Europe and Japan are established ARIKAYCE commercialization regions
  • •Future expansion depends on regulatory approvals in additional countries
  • •Patent protection is pursued in key markets including China and India
  • •Commercialization relies on local market access and distributor execution

INSMED is focused on growing revenue from its approved products while advancing a broader pipeline in respiratory,...

01
Commercialize approved products more broadlyshort-term

ARIKAYCE and BRINSUPRI are the only current revenue engines and fund the pipeline.

02
Advance late- and mid-stage pipeline assetsmedium-term

New approvals are needed to diversify revenue and reduce dependence on current products.

03
Build long-term rare disease and gene therapy optionalitylong-term

INS1201 and INS1202 could create new therapeutic franchises if clinical data are positive.

INSMED is highly dependent on the commercial success and regulatory status of ARIKAYCE and BRINSUPRI, so any setback in...

high

Dependence on approved products

ARIKAYCE and BRINSUPRI are the main commercial assets and drive current sales.

Scope
Commercial revenue concentration
Materiality
high
high

Regulatory and clinical development failure

Pipeline value depends on successful trials and approvals for TPIP, brensocatib, and gene therapies.

Scope
Pipeline programs
Materiality
high
high

Customer concentration

The three largest customers represented a very large share of gross product revenue.

Scope
Distributor and channel relationships
Materiality
high
medium

Manufacturing and supply dependence

Commercial supply relies on CMOs such as Patheon and API suppliers such as Esteve.

Scope
ARIKAYCE and BRINSUPRI supply chain
Materiality
medium
medium

Competitive pressure

Respiratory and rare disease markets include larger pharma and biotech competitors with more resources.

Scope
NTM, PAH, HS, DMD, ALS
Materiality
medium
Gross-to-net revenue reserves
Affects reported ARIKAYCE and BRINSUPRI revenue
Contingent consideration fair value
Can drive large non-cash gains or losses in earnings
Goodwill and intangible impairment
Potential non-cash charges to operating results
Revenue timing and quarterly volatility
Makes period-to-period comparison less stable

InMed Pharmaceuticals Inc.

INM · Pharmaceutical Preparations

Jasper Therapeutics, Inc.

JSPR · Biological Products, (No Diagnostic Substances)

INTENSITY THERAPEUTICS, INC.

INTS · Biological Products, (No Diagnostic Substances)

INCYTE CORP

INCY · Services-Commercial Physical & Biological Research

Invivyd, Inc.

IVVD · Biological Products, (No Diagnostic Substances)

Inhibrx Biosciences, Inc.

INBX · Biological Products, (No Diagnostic Substances)

: 28/04/2026